SEARCH:   Advanced

Blood, 15 September 2008, Vol. 112, No. 6, pp. 2429-2438. Prepublished online as a Blood First Edition Paper on July 8, 2008; DOI 10.1182/blood-2008-02-137877. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2008-02-137877v1 112/6/2429    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by James, C. Articles by de Verneuil, H. Search for Related Content PubMed PubMed Citation Articles by James, C. Articles by de Verneuil, H. Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA The hematopoietic stem cell compartment of JAK2V617F-positive myeloproliferative disorders is a reflection of disease heterogeneity Chloe James13, Frederic Mazurier1,2, Sabrina Dupont3,4, Ronan Chaligne3,4, Isabelle Lamrissi-Garcia1,2, Micheline Tulliez5, Eric Lippert1,2,6, François-Xavier Mahon1,2,6, Jean-Max Pasquet1,2, Gabriel Etienne1,2,7, François Delhommeau3,4,8, Stephane Giraudier3,9, William Vainchenker3,4,*, and Hubert de Verneuil1,2,* 1 Inserm, U876, Bordeaux; 2 Université V. Segalen Bordeaux 2, Bordeaux; 3 Institut Gustave Roussy, Inserm, UMR790, Villejuif; 4 Université Paris XI, Villejuif; 5 Laboratoire d'anatomie et de cytologie pathologique, Hopital Cochin, Assistance Publique-Hopitaux de Paris (AP-HP), Paris; 6 Laboratoire d'hématologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux; 7 Institut Bergonié, Bordeaux; 8 Laboratoire d'hématologie, Hopital Saint Antoine, AP-HP, Paris; and 9 Laboratoire d'hématologie, Hospital Henri Mondor, AP-HP, Créteil, France The JAK2V617F somatic point mutation has been described in patients with myeloproliferative disorders (MPDs). Despite this progress, it remains unknown how a single JAK2 mutation causes 3 different MPD phenotypes, polycythemia vera (PV), essential thrombocythemia, and primitive myelofibrosis (PMF). Using an in vivo xenotransplantation assay in nonobese diabetic-severe combined immunodeficient (NOD/SCID) mice, we tested whether disease heterogeneity was associated with quantitative or qualitative differences in the hematopoietic stem cell (HSC) compartment. We show that the HSC compartment of PV and PMF patients contains JAK2V617F-positive long-term, multipotent, and self-renewing cells. However, the proportion of JAK2V617F and JAK2 wild-type SCID repopulating cells was dramatically different in these diseases, without major modifications of the self-renewal and proliferation capacities for JAK2V617F SCID repopulating cells. These experiments provide new insights into the pathogenesis of JAK2V617F MPD and demonstrate that a JAK2 inhibitor needs to target the HSC compartment for optimal disease control in classical MPD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: F. Delhommeau, S. Dupont, V. D. Valle, C. James, S. Trannoy, A. Masse, O. Kosmider, J.-P. Le Couedic, F. Robert, A. Alberdi, et al. Mutation in TET2 in Myeloid Cancers N. Engl. J. Med., May 28, 2009; 360(22): 2289 - 2301. [Abstract] [Full Text] [PDF]

	Copyright © 2008 by American Society of Hematology         Online ISSN: 1528-0020